Research reports improved outcomes with mineralocorticoid receptor antagonists across different types of heart failure
Credit: Pixabay/CC0 Public Domain Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also